Success in the Middle of a Downturn: Strategies for Weathering the Biotech Storm and Building Trust in the Market The biotech industry has been facing a difficult economic climate, with market volatility, funding challenges, and increased competition. This session will discuss how biotechs are surviving and even thriving in the face of inflation and a bear market. - Uncover strategies for managing capital and resources wisely in a bear market, and staying afloat and attractive to investors in a downturn
- Assess methods to build and maintain trust and credibility with investors and talent and evaluate best practices for attracting and retaining talent
- Recognize the importance of effective leadership in driving growth and fostering innovation and how successful biotech leaders adapt and thrive during times of turmoil
- Discover how biotechs can find opportunities to innovate, partner and succeed in challenging times
|
The Inflation Reduction Act (IRA): The Dawn of a New Era - What Will it Mean for Innovation? (Balancing Inflation Reduction and Innovation) The biotech industry relies heavily on innovation and research and the passing of the Inflation Reduction Act (IRA) has created a new framework for how the industry prices and commercializes products. This panel will discuss the potential implications of the IRA for biotech innovation and research and how to move forward post implementation. - Review the key implications and effects of the IRA and the implications for the industry
- Consider the impact of the IRA on funding for biotech innovation and research including start-ups and VC investments
- Discover the pros and cons of the IRA for the biotech industry and how biotech companies can prepare for the regulatory changes
- Examine the impacts to healthcare access and affordability for the market
|
The Glass Ceiling is Cracked, What’s Next?
Strides have been made in recent years toward achieving gender diversity in biotech, but the fact remains that women are still significantly underrepresented in executive roles. While there is still work that needs to be done to dismantle gender biases and shatter the barriers that keep women out of biotech C-suites, the progress that has been achieved is a reason for optimism. Join Fierce Biotech staff writer Gabrielle Masson and a panel of trailblazing women as they explore how to drive change and see more women leaders in biotech. |
